Apollo Hospitals is not just a hospital chain - it is India’s largest and most complete private healthcare ecosystem, built over four decades to touch a patient at every point of care, from a neighbourhood pharmacy to a robotic brain surgery. It began in 1983 when Dr. Prathap C Reddy opened India’s first corporate hospital in Chennai, defying the notion that world-class care was only for the wealthy, and that same year it opened its first pharmacy, planting the seeds of a model that would eventually span hospitals, clinics, diagnostics, pharmacies, and a digital health platform. The recurring approach is to build a clinical asset of the highest complexity, earn trust, and then extend that trust into simpler, higher-volume touchpoints - pharmacies, diagnostics, primary clinics, and a digital app - so that the patient stays inside the Apollo system for life.
Business segments
Four engines at different stages - a mature hospital network that anchors the group, a pharmacy-distribution and digital platform being merged into a separate listed entity, a retail-health and diagnostics chain that feeds the hospitals, and a small but growing insurance and consumer-products layer - each built to capture a different part of the patient’s healthcare journey.
1. Healthcare Services: the high-acuity hospital network that earns the group’s reputation
Complex, life-saving procedures - cardiac, cancer, neuro, transplant - generate the clinical brand that makes every other part of the ecosystem credible.
- Fee-for-service on high-intensity episodes - the division earns revenue per inpatient stay, with an average of ₹187,208 per case in Q4 FY26, driven more by the complexity of the case mix than by simply filling more beds.
- “CONGO-T” specialties concentrate the skill - Cardiac, Oncology, Neurosciences, Gastroenterology, Orthopedics, and Transplant together form the clinical core; in FY26, cardiology alone brought in 19% of in-patient revenue and oncology 16%, meaning nearly two of every five rupees came from heart and cancer care.
- Technology as a magnet for patients and surgeons - the network houses South East Asia’s first proton therapy centre in Chennai, South Asia’s first ZAP-X radiosurgery platform for brain tumours, and India’s first AI-Precision Oncology Centre, all of which pull in complex cases that community hospitals cannot handle.
- Quality standards benchmarked to the world’s best - the Apollo Standards of Clinical Care (TASCC) scorecard tracks 40 clinical parameters against institutions like the Cleveland Clinic and Mayo Clinic, while JCI accreditation at eight hospitals makes the quality promise externally verifiable.
- A physical footprint that is still expanding - 78 hospitals with 10,970 capacity beds as of March 2026, with four new hospitals commissioned in FY26 alone and 3,415 more beds under development across 11 projects, including a greenfield hospital in Varanasi, a Build, Operate and Manage agreement in Mumbai, and a mix of greenfield, lease facility, and brownfield expansion in Bengaluru.
2. Apollo HealthCo: the pharmacy backbone and digital front door, soon to be a standalone listed company
A wholesale distribution engine that supplies 7,289 pharmacies and a digital platform with 47 million registered users - together forming an omni-channel health platform that is being merged with India’s largest pharma wholesaler and listed separately.
- Exclusive supplier to a nationwide pharmacy chain - the distribution business procures pharmaceuticals, FMCG, and private-label products and is the sole supplier to Apollo Pharmacies Limited under a long-term contract, giving it a procurement-cost advantage over local chemists and regional chains.
- Private label lifts margins - roughly 15.3% of omni-channel pharmacy sales in Q4 FY26 came from Apollo’s own private-label and generic products, which carry better economics than selling third-party brands.
- The digital platform turns trust into daily transactions - Apollo 24/7 handles approximately 15,000 doctor consultations and 51,600 medicine orders every day, with a customer-acquisition cost brought down to ₹250-400 per user by leaning on the Apollo brand and its 6,000-plus physical outlets rather than pure digital marketing spend.
- A Clinical Intelligence Engine that only Apollo could build - the platform’s AI-powered decision-support tool understands over 1,200 diseases and 800 symptoms prevalent in South Asia, trained on Apollo’s own clinical knowledge base and peer-reviewed by more than 500 of its specialists, a data moat no pure-tech competitor can replicate.
- The Keimed merger creates a distribution giant - a composite scheme of arrangement will demerge Apollo HealthCo, merge it with Keimed (which serves 70,000-plus pharmacies across 18 states with 96 distribution centres), and list the combined entity as Apollo Healthtech Limited, with AHEL shareholders owning 42.1% of the new company.
3. Apollo Health & Lifestyle: the out-of-hospital network that catches patients early and feeds the hospitals
A multi-brand chain of clinics, diagnostics labs, dialysis units, dental centres, and day-surgery facilities that operates on a hub-and-spoke model - treating everyday needs while identifying patients who need escalated hospital care.
- Diagnostics as the high-volume entry point - 2,501 centres including 114 labs and over 2,350 collection centres processed more than 8.6 million tests, with a central reference lab using AI to auto-validate 77% of results across 164 tests, speeding up turnaround in a business where speed wins customers.
- Each sub-brand targets a specific recurring need - Apollo Sugar manages diabetes with connected glucometers and long-term care packages, Apollo Dialysis runs units often under public-private partnership models with state governments, and Apollo Spectra performs short-stay surgeries in orthopedics, urology, and bariatrics, all on a fee-for-service basis.
- A feeder system for the tertiary hospitals - the hub-and-spoke design means a patient diagnosed at an Apollo Clinic or diagnostic centre can be referred directly into the main hospital network for complex treatment, keeping the patient within the Apollo ecosystem.
- The maternity and fertility business is being reshaped - in May 2026, AHLL agreed to sell its Apollo Cradle and Apollo Fertility centres to Cloudnine for cash of ₹7,650 million plus a roughly 9.9% equity stake in the combined entity, creating one of India’s largest maternity and fertility platforms while AHLL retains a stake in the upside.
4. Insurance and consumer products: early-stage bets on the edges of the ecosystem
A corporate insurance agency and a newly acquired FMCG distribution arm extend the Apollo brand into health coverage and everyday wellness products, both still nascent.
- Insurance sold without a field force - Apollo 24|7 Insurance Services Limited, incorporated in September 2024, acts as a corporate agent for life, general, and health insurance, distributing policies through digital channels and a 300-seat call centre rather than an agent network, keeping distribution costs low.
- Consumer products ride the pharmacy shelf space - Apollo Consumer Products Ltd, acquired in March 2026, will trade and distribute FMCG goods including food, personal care, and wellness products through the same physical retail and digital networks that already move pharmaceuticals, turning existing shelf space into a new revenue line.
Group structure and partners
A listed parent company with a web of subsidiaries that hold individual hospital assets, a soon-to-be-separated pharmacy and digital entity backed by Advent International, and a retail-health subsidiary that just became wholly owned - all governed by non-compete boundaries that keep each engine in its lane.
- Hospitals are held in asset-specific subsidiaries - individual hospitals in Kolkata, Lucknow, Bangalore, Ahmedabad, Guwahati, Indore, and other cities sit inside separate subsidiary companies, many with local minority partners, which isolates project-level risk and makes future stake sales or acquisitions cleaner.
- Advent International owns a slice of the pharmacy-digital business - the private-equity firm invested ₹2,475 crore in Apollo HealthCo in September 2024 for approximately 16.9%, and will hold 12.1% of the post-merger Apollo Healthtech entity, aligning external capital with the listing catalyst.
- A non-compete framework keeps the engines from colliding - under a Business Framework Agreement, AHEL cannot run an e-commerce or retail pharmacy business outside its hospital pharmacies, while Apollo HealthCo cannot deliver physical healthcare services; the Apollo 24/7 platform remains the exclusive digital front-end for the entire group.